12-6-04

Express Mail No. EV519867025US

1632\$ EN UCAL-222 Attorney Docket WEISGRABER, KARL H. First Named Inventor **Application Number** 10/017,718 Filing Date December 14, 2001 1632 Group Art Unit

Address to: Mail Stop AF Commissioner for Patents P.O. Box 1450

ORMATION DISCLOSURE

STATEMENT

UNDER 37 CFR § 1.97(D)

TON, THAIAN N. **Examiner Name** "GENE-TARGETED ANIMAL MODEL OF APOLIPOPROTEIN E4 DOMAIN INTERACTION AND USES THEREOF"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. This is being filed after a Final Action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee.

Title:

A Form SB08 (substitute for form 1449) listing the references accompanies this paper. Applicants would appreciate the Examiner initialing and returning the form to indicate that the references have been reviewed and made of record.

Statement(s) under 37 CFR § 1.97(e):

- (1) That each item of information contained in the information disclosure statement was first X cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
- (2) That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

12/07/2004 JBALINAN 00000065 500815 10017718

01 FC:1806 180.00 DA

Atty Dkt. No.: UCAL-222 USSN: 10/017,718

In accordance with the requirements of 37 C.F.R. §1.97(d) accompanying this paper is a certification as specified in 37 C.F.R. §1.97(e). Applicant(s) hereby petition for the consideration of this Information Disclosure Statement.

The \$180.00 fee set forth in 37 C.F.R. §1.17(p) to cover the petition accompanies this disclosure statement. The Office is hereby authorized to charge any additional fees which may be required by this paper or any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21, or to credit any overpayment, to our Deposit Account No. 50-0815, Order No. UCAL-222 may be charged thereon.

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

Date: <u>Dec. 3, 2004</u>

Paula A. Borden, Reg. No. 42,344

BOZICEVIC, FIELD & FRANCIS LLP 1900 University Avenue, Suite 200 East Palo Alto, California 94303

Telephone: (650) 327-3400 Facsimile: (650)327-3231

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

E DEM Complete if Known Substitute for form 1449B/PTO **Application Number** 10/017,718 INFORMATION DISCLOSURE Filing Date December 14, 2001 STATEMENT BY APPLICANT First Named Inventor WEISGRABER, KARL H. Group Art Unit 1632 **Examiner Name** (use as many sheets as necessary) TON, THAIAN N. Sheet 1 Attorney Docket Number **UCAL-222**

OTHER ART—NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),		T²	
		Plump A.S. et al., "Severe Hypercholesterolemia and Atherosclero Created by Homologous Recombination in ES Cells" Cell, Cel October 16, 1992, pgs. 343-353	osis in Apollp I Press, Can	oprotein E-Deficient Mice abridge, NA, US, Vo. 71,	
	·	Ree van J.H. et al., "Inactivation of Apoe and Apoc1 by Two Co Effects on mRNA Expression Levels of Gene Cluster Members University Press, Surrey, GB, Vol. 4, No. 8, August 8, 1995, pgs. 14	" Human Mo	ounds of Gene Targeting: lecular Genetics, Oxford	
		·			
				*	
			_		
				-	
F					
Examiner Signature			Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.